The CPS team oversees the ordering, analysis, interpretation, and counseling associated with pharmacogenomic testing at Boston Children’s Hospital. The available tests include analysis of genes affecting medication breakdown, transport, and response. Results from these tests are analyzed by the CPS team to provide any insight into past medication history and to guide future prescribing decisions to help ensure that medications are chosen and dosed in a manner that is safe and effective as far as possible. When genetic variants of significance are detected, results may suggest that increased monitoring for side effects or dose changes are appropriate for certain medications due to modified medication breakdown. Findings may also suggest the prioritization of specific medications or medication classes based on predicted response. In other instances, total avoidance of particular medications may be recommended due to increased risk of serious adverse drug events. The results are also valuable even when no significant variants are detected, as prescribers can be reassured that therapeutic modification based on genetic factors is not necessary.
Our approach to patient care is interdisciplinary, with specially trained pharmacists and geneticists working in tandem to provide the most current perspectives, recommendations, and guidance pertaining to pharmacogenomics. We collaborate with prescribers from all specialties to incorporate findings into the clinical decision making process where appropriate. Our expectation is that by finding the right medications and doses that work best for you, we can reduce side effects, increase your chances of successful treatment, and help you achieve better health outcomes.